Premium
One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults
Author(s) -
Beentjes John A. M.,
Gorkom Britta A. P.,
Sluiter Wim J.,
Vries Elisabeth G. E.,
Kleibeuker Jan H.,
Dullaart Robin P. F.
Publication year - 2000
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1046/j.1365-2265.2000.00993.x
Subject(s) - medicine , endocrinology , placebo , acromegaly , crypt , immunostaining , colorectal cancer , lanreotide , gastroenterology , growth hormone , hormone , cancer , immunohistochemistry , pathology , alternative medicine
Summary OBJECTIVE Increased colonic epithelial cell proliferation has been found in various conditions associated with increased risk of colorectal cancer including acromegaly. In a placebo‐controlled study we determined the effect of growth hormone (GH) replacement therapy in GH deficient adults on the colonic epithelial proliferation rate. PATIENTS AND DESIGN Sixteen GH deficient adults were randomised to low dose GH therapy (1 U (0.5 mg) subcutaneously per day, n =5), high dose GH therapy (2U daily, n =5) or placebo ( n = 6) during 6 months. Thereafter, all patients were treated with 2U of GH daily during a 6‐months open extension period. MEASUREMENTS Plasma Insulin‐like growth hormone I (IGF‐I) and IGF binding protein 3 (IGF BP3) concentrations were measured using commercial RIA kits. The colonic epithelial proliferation rate, expressed as overall crypt labelling index (LI) using 5‐bromo‐2′‐deoxyuridine (BrdU) immunostaining, was determined at baseline, after 6 months treatment and at the end of the 6 months open extension period. RESULTS IGF‐I rose from 8.9±6.7 to 34.6 ±20.0 nmol/l after 6 months in 8 GH treated patients ( P <0.01 from baseline; P <0.01 from change with placebo). In the extension study, plasma IGF‐I was also increased in the patients who previously received placebo ( P <0.02, n= 5). LI was evaluable in 14 biopsies at baseline, in 16 after 6 months and in 14 after 12 months. Overall crypt LI did not change in 8 GH treated patients after 6 months ( P < 0.40 from baseline; P >0.80 from change with placebo). In the extension study, overall crypt LI was also unchanged in those patients who received GH after placebo ( n = 5, P >0.40) and in those who continued GH replacement ( n =9, P >0.60; P >0.80 from change in initially placebo treated patients). Separate evaluation of the LI at the basal, mid and luminal portions of the colonic crypts also did not reveal any effect of GH treatment on BrdU labelling. CONCLUSIONS Six to 12 months of GH replacement therapy, aimed to increase plasma IGF‐l into the (high) physiological range, does not adversely affect colonic epithelial cell proliferation as a biomarker for the risk of development of colorectal cancer.